Atomic AI

Atomic AI is a private, pre-clinical stage biotech founded in 2021, operating at the intersection of artificial intelligence and RNA therapeutics. The company has built a proprietary R&D platform that integrates its ATOM-1 deep learning model for RNA structure prediction with in-house wet-lab assays to accelerate drug discovery. By unlocking the 3D structure of RNA, Atomic AI aims to open a new frontier of drug targets for small molecules and RNA-based therapeutics, positioning itself in the rapidly growing field of computational drug discovery.

Proprietary R&D platform integrating the ATOM-1 foundation model for atomic-precision prediction of RNA 3D structure with a closed-loop system of in-house wet-lab assays. This 'virtuous cycle' uses experimental data to continuously refine the AI models for drug discovery.

Atomic AI competes in the broad AI-drug discovery space with companies like Recursion, Exscientia, and Insilico Medicine, and more specifically in the RNA structure prediction and targeting niche with academics and biotechs like Arrakis Therapeutics, Remix Therapeutics, and Expansion Therapeutics. Its differentiation lies in its specialized focus on RNA 3D structure via its ATOM-1 model.